https://www.webdisclosure.com/article/nuvaxovid-de-sanofi-presente-une-meilleure-tolerance-face-au-mnexspike-1TGJE5idq7Z 2026-04-18T10:05:00.000Z WebDisclosure fr 2026-04-18T10:05:00.000Z Nuvaxovid de Sanofi présente une meilleure tolérance face au mNEXSPIKE Blog SANOFI-AVENTIS,FR0000120578,SAN,bourse,business,économie,finance,Sanofi,Tolérance,Nuvaxovid,Vaccination COVID-19,ESCMID EPA:SAN https://data.webdisclosure.com/images/HcJSKkzg16O.jpg https://www.webdisclosure.com/article/sanofis-nuvaxovid-demonstrates-better-tolerability-compared-to-mnexspike-Ic3n9MfeJCj 2026-04-18T10:05:00.000Z WebDisclosure en 2026-04-18T10:05:00.000Z Sanofi's Nuvaxovid demonstrates better tolerability compared to mNEXSPIKE Blog SANOFI-AVENTIS,FR0000120578,SAN,bourse,business,economy,finance,Sanofi,Tolérance,Nuvaxovid,ESCMID,COVID-19 Vaccination EPA:SAN https://data.webdisclosure.com/images/HcJSKkzg16O.jpg https://www.webdisclosure.com/article/sanofis-vaccine-shows-superior-tolerability-in-recent-study-TfYQdozAify 2026-04-18T10:05:00.000Z WebDisclosure en 2026-04-18T10:05:00.000Z Sanofi's Vaccine Shows Superior Tolerability in Recent Study Blog SANOFI-AVENTIS,FR0000120578,SAN,bourse,business,economy,finance,COVID-19,Sanofi,Nuvaxovid,Vaccine Study,Tolerability EPA:SAN https://data.webdisclosure.com/images/HcJSKkzg16O.jpg https://www.webdisclosure.com/article/le-vaccin-de-sanofi-presente-une-tolerance-superieure-selon-une-etude-recente-42n3kl9Mxds 2026-04-18T10:05:00.000Z WebDisclosure fr 2026-04-18T10:05:00.000Z Le vaccin de Sanofi présente une tolérance supérieure selon une étude récente Blog SANOFI-AVENTIS,FR0000120578,SAN,bourse,business,économie,finance,Sanofi,COVID 19,Tolérance,Nuvaxovid,Étude Sur Les Vaccins EPA:SAN https://data.webdisclosure.com/images/HcJSKkzg16O.jpg https://www.webdisclosure.com/press-release/communique-de-presse-escmid-le-nuvaxovid-vaccin-contre-la-covid-19-de-sanofi-a-montre-une-meilleure-tolerance-que-le-mnexspike-dans-une-etude-comparative-directe-wmXE8erm6SX 2026-04-18T10:00:00.000Z WebDisclosure fr 2026-04-18T10:00:00.000Z Communiqué de presse : ESCMID : Le Nuvaxovid, vaccin contre la COVID-19 de Sanofi, a montré une meilleure tolérance que le mNEXSPIKE dans une étude comparative directe PressRelease SANOFI-AVENTIS,FR0000120578,SAN,bourse,business,économie,finance,COVID-19,Sanofi,Vaccin,Tolérance,Nuvaxovid EPA:SAN https://www.webdisclosure.com/press-release/press-release-escmid-sanofis-nuvaxovid-covid-19-vaccine-showed-better-tolerability-than-mnexspike-in-head-to-head-study-maJJhtVEoL9 2026-04-18T10:00:00.000Z WebDisclosure en 2026-04-18T10:00:00.000Z Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study PressRelease SANOFI-AVENTIS,FR0000120578,SAN,bourse,business,economy,finance,COVID-19,Sanofi,Vaccine,Nuvaxovid,Tolerability EPA:SAN https://www.webdisclosure.com/article/formation-metals-repond-aux-preoccupations-liees-aux-activites-promotionnelles-aZJ0BUjmBzq 2026-04-18T02:05:00.000Z WebDisclosure fr 2026-04-18T02:05:00.000Z Formation Metals répond aux préoccupations liées aux activités promotionnelles Blog Formation Metals,CA34638F1053,FOMO,bourse,business,économie,finance,Relations Avec Les Investisseurs,Volume Des Échanges,Métaux De Formation,Marchés De Gré À Gré,Activité Promotionnelle https://www.webdisclosure.com/article/formation-metals-addresses-promotional-activity-concerns-ODwh4X1V54j 2026-04-18T02:05:00.000Z WebDisclosure en 2026-04-18T02:05:00.000Z Formation Metals Addresses Promotional Activity Concerns Blog Formation Metals,CA34638F1053,FOMO,bourse,business,economy,finance,Investor Relations,OTC Markets,Trading Volume,Formation Metals,Promotional Activity https://www.webdisclosure.com/press-release/formation-metals-responds-to-otc-markets-request-on-recent-promotional-activity-yQeOiOlJEOk 2026-04-18T02:00:00.000Z WebDisclosure en 2026-04-18T02:00:00.000Z Formation Metals Responds to OTC Markets Request on Recent Promotional Activity PressRelease Formation Metals,CA34638F1053,FOMO,bourse,business,economy,finance,Investor Relations,OTC Markets,Formation Metals Inc.,Promotional Activity,Third-party Marketing Firms https://www.webdisclosure.com/article/aiml-innovations-completes-share-issuance-M8TMop5eSJ8 2026-04-18T00:05:00.000Z WebDisclosure en 2026-04-18T00:05:00.000Z AI/ML Innovations Completes Share Issuance Blog AI/ML Innovations Inc.,CA00143Y1034,AIML,bourse,business,economy,finance,Debt Settlement,Related Party Transaction,AI/ML Innovations,Share Issuance,Securities Regulation https://www.webdisclosure.com/article/aiml-innovations-finalise-son-emission-dactions-I1vLDFQgtV5 2026-04-18T00:05:00.000Z WebDisclosure fr 2026-04-18T00:05:00.000Z AI/ML Innovations finalise son émission d'actions Blog AI/ML Innovations Inc.,CA00143Y1034,AIML,bourse,business,économie,finance,Émission D'actions,Réglementation Des Valeurs Mobilières,Opération Entre Parties Liées,Règlement De Dettes,Innovations En IA/ML https://www.webdisclosure.com/press-release/aiml-innovations-announces-completion-of-share-issuance-WRC0RFgbs25 2026-04-18T00:00:00.000Z WebDisclosure en 2026-04-18T00:00:00.000Z AI/ML Innovations Announces Completion of Share Issuance PressRelease AI/ML Innovations Inc.,CA00143Y1034,AIML,bourse,business,economy,finance,AI/ML Innovations Inc.,Share Issuance,Insiders,Debt,Statutory Hold Period https://www.webdisclosure.com/article/medicure-announces-leadership-change-bDbjIuVMnGc 2026-04-17T23:40:00.000Z WebDisclosure en 2026-04-17T23:40:00.000Z Medicure Announces Leadership Change Blog Medicure, Inc.,CA58469E4085,MCUJF,bourse,business,economy,finance,Pharmaceuticals,Strategic Priorities,Medicure Inc.,Leadership Change,United States Market NASDAQ:MCUJF https://www.webdisclosure.com/article/medicure-annonce-un-changement-de-direction-CpFfGgR8f24 2026-04-17T23:40:00.000Z WebDisclosure fr 2026-04-17T23:40:00.000Z Medicure annonce un changement de direction Blog Medicure, Inc.,CA58469E4085,MCUJF,bourse,business,économie,finance,Medicure Inc.,Médicaments,Changement De Leadership,Priorités Stratégiques,Marché Des États-Unis NASDAQ:MCUJF https://www.webdisclosure.com/press-release/medicure-announces-resignation-of-president-and-chief-operating-officer-Xd0LFVklBV2 2026-04-17T23:35:00.000Z WebDisclosure en 2026-04-17T23:35:00.000Z Medicure Announces Resignation of President and Chief Operating Officer PressRelease Medicure, Inc.,CA58469E4085,MCUJF,bourse,business,economy,finance,Pharmaceuticals,Resignation,Healthcare,Medicure Inc.,Leadership NASDAQ:MCUJF https://www.webdisclosure.com/article/onco-innovations-enhances-leadership-with-key-appointments-610ITz10JB2 2026-04-17T23:05:00.000Z WebDisclosure en 2026-04-17T23:05:00.000Z Onco-Innovations Enhances Leadership with Key Appointments Blog Onco-Innovations Limited,CA68237C1059,ONCO,bourse,business,economy,finance,Clinical Trials,Executive Appointments,Oncology Development,Research Strategy,Leadership In Biotechnology https://www.webdisclosure.com/article/onco-innovations-renforce-son-equipe-dirigeante-grace-a-des-nominations-cles-YkwDaDn3fH3 2026-04-17T23:05:00.000Z WebDisclosure fr 2026-04-17T23:05:00.000Z Onco-Innovations renforce son équipe dirigeante grâce à des nominations clés Blog Onco-Innovations Limited,CA68237C1059,ONCO,bourse,business,économie,finance,Essais Cliniques,Leadership En Biotechnologie,Développement En Oncologie,Nominations De Cadres Supérieurs,Stratégie De Recherche https://www.webdisclosure.com/press-release/onco-innovations-strengthens-executive-leadership-with-appointment-of-dr-islam-mohamed-as-chief-medical-officer-and-stephen-m-novak-as-chief-of-research-and-development-txxB3Tx9Y0i 2026-04-17T23:00:00.000Z WebDisclosure en 2026-04-17T23:00:00.000Z Onco-Innovations Strengthens Executive Leadership with Appointment of Dr. Islam Mohamed as Chief Medical Officer and Stephen M. Novak as Chief of Research and Development PressRelease Onco-Innovations Limited,CA68237C1059,ONCO,bourse,business,economy,finance,Appointment,Clinical Development,R&D,Onco-Innovations,ONC010